Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.
By A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, A. Rapoport, R. Fenton, Natalie Gahres, E. Sausville, R. Ord and 1 more. Journal of Clinical Oncology, 2006
603 citations recorded by the source corpus.
Subfields: Oncology, Orthopedics and Sports Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/ed5d6d69ca09a202711ad3bb86f9890633bc6ddd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Orthopedics and Sports Medicine
Citations in the corpus
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. (2012, background): “Studies suggest that the risk of ONJ may increase with the potency of the antiresorptive agent and duration of treatment [1, 3, 5, 14, 15, 18, 20].”
- Medication-Related Osteonecrosis of the Jaw—2014 Update (2014, background): “BPs (both dose of BP and duration of exposure impact ONJ risk)((24)); zoledronic acid((83,105,112,150,164)); pamidronate((150)); Dmab (from incidence and prevalence data); radiation therapy((24)); dental extraction((24,105,150,161,165)); chemotherapy((84)); periodontal disease((166)); oral BP use((2”
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus (2015, neutral): “BPs (both dose of BP and duration of exposure impact ONJ risk)((24)); zoledronic acid((83,105,112,150,164)); pamidronate((150)); Dmab (from incidence and prevalence data); radiation therapy((24)); dental extraction((24,105,150,161,165)); chemotherapy((84)); periodontal disease((166)); oral BP use((2”